Because Aβ accumulation has been considered the initial attack that prompts either the tau pathology or tau‐mediated neurodegeneration in AD, and hence the development of AD medication has focused chiefly on removing Aβ from the brain.3 This evidence concerns the gene MAPT and Alzheimer disease.